- Home
- IHT vs IMRN Comparison
IHT vs IMRN Comparison
Compare IHT & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IHT
- IMRN
- Stock Information
- Founded
- IHT 1971
- IMRN 1994
- Country
- IHT United States
- IMRN Australia
- Employees
- IHT N/A
- IMRN N/A
- Industry
- IHT Investment Bankers/Brokers/Service
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- IHT Finance
- IMRN Health Care
- Exchange
- IHT Nasdaq
- IMRN Nasdaq
- Market Cap
- IHT 15.6M
- IMRN 15.0M
- IPO Year
- IHT N/A
- IMRN N/A
- Fundamental
- Price
- IHT $1.84
- IMRN $2.69
- Analyst Decision
- IHT
- IMRN Strong Buy
- Analyst Count
- IHT 0
- IMRN 1
- Target Price
- IHT N/A
- IMRN $5.00
- AVG Volume (30 Days)
- IHT 7.1K
- IMRN 5.6K
- Earning Date
- IHT 10-15-2024
- IMRN 10-15-2024
- Dividend Yield
- IHT 1.09%
- IMRN N/A
- EPS Growth
- IHT N/A
- IMRN N/A
- EPS
- IHT N/A
- IMRN N/A
- Revenue
- IHT $7,691,676.00
- IMRN $3,271,194.00
- Revenue This Year
- IHT N/A
- IMRN N/A
- Revenue Next Year
- IHT N/A
- IMRN N/A
- P/E Ratio
- IHT N/A
- IMRN N/A
- Revenue Growth
- IHT 6.27
- IMRN 171.67
- 52 Week Low
- IHT $1.11
- IMRN $1.48
- 52 Week High
- IHT $2.25
- IMRN $5.96
- Technical
- Relative Strength Index (RSI)
- IHT 47.54
- IMRN 51.76
- Support Level
- IHT $1.82
- IMRN $2.66
- Resistance Level
- IHT $1.87
- IMRN $2.87
- Average True Range (ATR)
- IHT 0.11
- IMRN 0.11
- MACD
- IHT -0.02
- IMRN 0.00
- Stochastic Oscillator
- IHT 22.15
- IMRN 54.85
About IHT InnSuites Hospitality Trust Shares of Beneficial Interest
InnSuites Hospitality Trust is a real estate investment trust. It is engaged in the ownership and operation of hotel properties. It owns and operates hotels, provides management services for hotels, and also provides trademark license services. The Trust is also involved in various operations incidental to the operation of hotels, such as the operation of restaurants, meeting/banquet room rentals, and the operation of a reservation system. It has one reportable segment Hotel Operations & Hotel Management Services.
About IMRN Immuron Limited
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.